Study Summaries

The combination of palbociclib and letrozole significantly improved PFS compared to placebo with letrozole. However, it was associated with higher hematologic toxicities, particularly neutropenia.

The combination of abemaciclib and fulvestrant shows promising efficacy and manageable toxicity in HR-positive advanced or recurrent endometrial cancer, especially in CN-L/NSMP tumors

First-line lenvatinib plus pembrolizumab did not significantly improve PFS or OS compared to chemotherapy in mismatch repair-proficient (pMMR) advanced endometrial cancer. Toxicity was higher in the experimental arm but manageable. dMMR exploratory analysis shows promise in this subgroup.

HIPEC combined with cytoreductive surgery significantly improved overall survival and progression-free survival in recurrent ovarian cancer

Olaparib combined with bevacizumab provided a OS benefit for HRD-positive ovarian cancer patients.

Adjuvant Pembrolizumab did not improve DFS in high-risk endometrial cancer population

HIPEC combined with ICS significantly improved PFS and OS in advanced-stage ovarian cancer patients, without increasing the rate of severe postoperative complications. A notable reduction in peritoneal recurrence may contribute to the OS improvement.